Fiche centre
Raleigh Neurology Associates
Raleigh — United States
Essais liés7clinical trials
VilleRaleighlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02807285
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT01194570 | ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | COMPLETED |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |